Kronos Bio Corp (KRON) Net earnings per share growth forecast for next year

Corporate company logo of Kronos Bio, Inc. (KRON)

Consensus expectations for n+1 profit dynamics demonstrate a vector of expansion for Kronos Bio, Inc. (KRON) via CDK9 inhibitors to capture the oncology market. The value of 0.00 expresses the latest metric level as the company cuts costs and seeks partners for molecule licensing. However, investors should be wary of the rapid cash burn and the uncertainty of clinical trial outcomes, which create significant financial risks.

Kronos Bio Corp (KRON): Net earnings per share growth forecast for next year from 07/04/2022 to 06/28/2025

Summary analytical data breakdowns for kronosbio.com (KRON)

- share price and consensus valuation forecast:
Stock Price Kronos Bio Corp|KRON - Consensus Target
- market capitalization details:
Market Value Kronos Bio|KRON - Total Enterprise Value
- company book value details:
Net Assets per Single Share Kronos Bio|KRON - Company Book Value|Market Value to Book Value Ratio kronosbio.com|KRON - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Kronos Bio, Inc.|KRON - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Kronos Bio|KRON - Company Cumulative Debt|Debt to Book Value Kronos Bio|KRON - Company Long-Term Loans and Borrowings|Company Current Liabilities Kronos Bio|Quick Ratio kronosbio.com
- net income and valuation ratios data:
KRON - Final Profit|Projected Future Earnings Kronos Bio, Inc.|KRON - Market Cap to Earnings|Future Price to Earnings Kronos Bio, Inc.|KRON - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Kronos Bio|KRON - Operating profit EBITDA|Earnings per share for the last twelve months Kronos Bio|KRON - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months kronosbio.com|KRON - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Kronos Bio, Inc.
Fundamental company analysis:Kronos Bio Corp
Finished products of Kronos Bio Inc

For Kronos Bio, Inc. (KRON), which develops innovative methods to combat resistant tumors, profit dynamics depend directly on the success of clinical trials for targeted drugs. The GURU.Markets toolkit, via forward earnings per share (EPS) growth forecasts, allows investors to filter out market noise by measuring analyst consensus expectations for future returns to assess the fundamental capital stability of the company.

Competitor analysis for Kronos Bio, Inc.

INCY (Incyte Corp.) - Earnings growth forecast for next year|Expected earnings per share growth for next year HUTCHMED Corp (HCM)|Net earnings per share growth forecast for next year Nuvation Bio Inc. (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Therapeutics Inc. MNPR|Inhibrx - Net earnings per share growth forecast for next year|IMAB - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Fennec|HRTX: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year nuvectis.com NVCT|Expected earnings per share growth for next year CHRS|Expected net earnings per share growth next year Corbus Pharmaceuticals Holdings, Inc. CRBP|Expected earnings per share growth for next year CRDF (Cardiff Oncology, Inc.)|BYSI (BeyondSpring Inc) - Expected earnings per share trend next year|BioAtla - Expected earnings per share growth for next year|Projected earnings per share increase next year LIXT (lixte.com)|Citius Pharma - Earnings growth forecast for next year|Expected earnings per share trend next year CLRB (Cellectar Biosciences Inc)|BLRX: Earnings growth forecast for next year|Expected net earnings per share growth next year Can-Fite (CANF)|Net earnings per share growth forecast for next year Aprea Therapeutics Inc.|KZIA: Expected earnings per share trend next year|Earnings growth forecast for next year SLXN|Earnings growth forecast for next year nucana.com (NCNA)|Net earnings per share growth forecast for next year Chimerix, Inc CMRX|CYCC (Cyclacel, Inc.) - Net earnings per share change forecast for next year|GTHX: Expected earnings per share growth for next year|Expected net earnings per share growth next year kintara.com|Oncternal Therapeutics, Inc. (ONCT) - Net earnings per share growth forecast for next year|Portage Biotech Inc (PRTG) - Earnings growth forecast for next year